THE POTENCY OF SOURSOP LEAF WATER EXTRACT ON ACTIVATING GLP-1R, INHIBITING DPP4 AND FOXO1 PROTEIN BASED ON IN SILICO ANALYSIS by DAMAYANTI, DINI SRI et al.
 
 
    SSN - 0975-7058 










THE POTENCY OF SOURSOP LEAF WATER EXTRACT ON ACTIVATING GLP-1R, INHIBITING
DPP4 AND FOXO1 PROTEIN BASED ON IN SILICO ANALYSIS
DINI SRI DAMAYANTI1,2, NURDIANA3, H. M. S. CHANDRA KUSUMA4, DJOKO WAHONO SOEATMADJI5
1Doctoral Program Medical Science, Faculty of Medicine, Universitas Brawijaya, Malang, 65145, Indonesia, 2Department of Physiology,
Faculty of Medicine, Universitas Islam, Malang, 65144, Indonesia, 3Department of Pharmacology, Faculty of Medicine, Universitas 
Brawijaya, Malang, 65145, Indonesia, 4Department of Pediatric Medicine, Faculty of Medicine, Universitas Brawijaya, Malang, 65145,
Indonesia, 5Department of Internal Medicine, Faculty of Medicine, Universitas Brawijaya, Malang, 65145, Indonesia.
Email: dinisridamayanti@gmail.com
Received: 12 Dec 2018, Revised and Accepted: 10 Mar 2019 
ABSTRACT 
Objective: Soursop leaf contains alkaloids, terpenoids, flavonoids, acetogenin, and phenolics. Soursop leaf decoction is usually consumed as an anti-
obesity agent, even though its active compounds and its action mechanism are still unclear. Computational approaches have been developed to 
predict the ability of an active compound to bring about biological effects. This study was designed to predict the potency of soursop (Annona 
muricata Linn.) water extract for the activating of Glucagon-Like Peptide-1 Receptor (GLP-1R), Inhibiting Dipeptidyl Peptidase 4 (DPP4), and 
Forkhead Box Protein O1 (FoxO1) protein using in silico analysis. 
Methods: Identification of active compounds contained in soursop leaf water extract was carried out using physicochemical methods and Gas 
chromatography–mass spectrometry (GC-MS). They were then analyzed using computational analysis, i.e., potential analysis using the Way2drug 
web server. Protein interaction predictions of GLP-1R with the active compounds found in soursop leaf water extract using STITCH. The affinities of 
the active compounds of soursop leaf to the proteins DPP4 and FoxO1 were also analyzed using molecular docking. 
Results: Active compounds of the soursop leaf water extract contain 5-isopropenyl-3,8-dimethyl-1,2,3,3A, 4,5,6,7-octa hydro azulene (22.17%) and 
1,2-benzene dicarboxylic acid, diethyl ester (phthalic acid) (57.30%). The active ingredients have not been shown to interact with GLP-1R. 5-
isopropenyl-3,8-dimethyl-1,2,3,3A, 4,5,6,7-octa hydro azulene and phthalic acid both have a weak affinity for DPP4, and only phthalic acid has a 
weak affinity with the FoxO1 protein. 
Conclusion: Phthalic acid has a weak potential as an inhibitor of the DDP4 and FoxO1 proteins. 
Keywords: GLP-1 Receptor, DPP4, FoxO1, soursop leaf (Annona muricata l.) 
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INTRODUCTION 
Traditional health services in Indonesia, especially in rural 
communities compared to urban communities. A total of 49% of the 
89,753 households in Indonesia use traditional health services such as 
aromatherapy, and spas as medicinal treatment [1]. There is a belief 
that herbal treatments can cure various diseases and are cheap [2, 3]. 
Many Indonesian people believe that traditional medicine is better 
than modern medicine [1], and continue to consume the traditional 
medicine, often in the form of herbal decoctions [3]. 
One of the herbs that is widely used in traditional health treatments is 
soursop leaves (Annona muricata Linn.). Soursop plants are native to 
South America and have now spread to Southeast Asia, Southern 
Europe, South China, Africa, Australia, and the Pacific. Soursop is a type 
of plants with dense leaves and a height ranging from 8-9 meters. The 
leaves are oval-shaped, and its size are 6.5 cm x 2.5 cm they are dark 
green and shiny on the top. Its flowers are single flowers which appear 
on stems, branches, and twigs. Its fruit can be consumed. The young 
fruit is dark green with a rough surface, and there are bumps like 
spines. When it is ripe, it becomes brownish-yellow, and the fruits 
texture is fibrous, soft, and segmented. The fruit tastes sweet-sour 
with a pineapple-like aroma. The seeds are blackish-brown and oval-
shaped, with a size of 2.5 x 0.5 cm (fig. 1) [4]. 
As an herbal plant, soursop leaves are consumed by the community 
as an antihypertensive agent [5], anti-diabetic [6], anti-inflammatory 
[7], anti-obesity [8], antioxidant [9], anti-hyperlipidemic [10], anti-
rheumatic [11], antibacterial [12], antidepressant [13], and 
anticancer [14]. Soursop leaves contain active compounds, including 
acetogenin [15], alkaloids, terpenoids, flavonoids, coumarins, 
steroids, fatty acids, phlorotannins, phenolics, tannins, and saponins 
[16]. Although soursop leaves have been shown to have anti-obesity 
effects in multiple in vivo studies, the mechanism by which its active 
ingredients, individually or in combination, might act as anti-obesity 
agents have not been studied. 
 
Fig. 1: Soursop leaves and fruit (private collection) 
 
Obesity is a condition caused by an imbalance between food intake 
and energy expenditure that causes the accumulation of adipose 
cells in the subcutaneous and visceral tissue. Data from the World 
Health Organization (WHO) stated that the number of obese patients 
in the world had increased dramatically since 1980. This increase in 
the number of obese patients is related to environmental factors 
such as unhealthy eating habits and a lack of activity [17]. Obesity is 
a predisposing factor for type 2 diabetes mellitus, fatty liver, 
cardiovascular disease, reproductive disease, malignancy, 
osteoarthritis and psychosocial disorders [18]. 
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The development of pharmacological treatments for obese patients 
emphasizes the role of intestinal peptides, namely GLP-1 [19]. 
Several studies have shown impaired function of GLP-1 in obese 
patients. This is presumed to be the cause of a decrease in hunger 
suppression signaling and an increase in gastric emptying [20]. GLP-
1 is a peptide hormone composed of 30 peptides. GLP-1 is secreted 
by intestinal L cells in response to food in the food channel, 
especially for glucose, protein, a lipid; this is parasympathetic nerve 
activity. L cells are widely distributed in the jejunum distal, ileum, 
colon and rectum [21]. The proglucagon gene encodes GLP-1. 
Preproglucagon genes are expressed in the L cells, pancreatic α cells 
and neurons in the solitary tract. 
Post-translation of preproglucagon genes increases the expression 
of the proglucagon gene. The type of peptide formed by proglucagon 
depends on the activity of the specific Prohormone Convertase (PC) 
enzyme in the tissue. Prohormone Convertase-2 (PC2) expression is 
abundant in pancreatic α cells. This condition causes proglucagon to 
synthesize Glucagon peptides, Intervening Peptide-1 (IP1), and 
Major Proglucagon Fragment (MPGF). As for L cells in the intestine, 
the activity of the Prohormone Convertase-1 (PC1) enzyme will 
break down proglucagon to GLP-1, GLP-2, oxyntomodulin, glicentin, 
and Intervening Peptide-2 (IP2) [22]. 
GLP-1 is secreted in 2 active forms, namely GLP-1 (7-36 amino acid 
residues) and GLP-1 (7-36) amide. GLP-1 (7-36) amide is the most 
distributed form in the circulatory system. Structurally, GLP-1 is 
similar to glucagon. GLP-1 is composed of N terminal segments (1-7 
amino acid residues), 2 helix segments (7-14 and 18-29), and 
connecting segments (15-17 amino acid residues. GLP-1 is 
eliminated from the circulatory system via excretion via the kidneys, 
and liver, and inactivation by the enzyme DPP4. The half-life of GLP-
1 is about 1-2 min due to inactivation by the DPP4 enzyme in the 
circulation. DPP4 will cut GLP-1 (7-36) and GLP-1 (7-36) amides to 
form GLP-1 (9-36) which is inactive [21]. 
GLP-1 receptors are located in the islet of Langerhans (cells α, β, δ 
pancreas), gastric parietal cells, brain, heart, lung, and kidneys. This 
receptor is not found in skeletal muscle tissue, liver, or adipose 
tissue [18]. GLP-1 receptors belong to the G protein couple receptor 
(GPCR) family. This receptor has an extracellular N-terminal domain 
(NTD) consisting of 100-150 peptides that are associated with 
integral membrane core domains (J domains) [23]. 
GLP-1 plays a role in regulating blood glucose levels through the 
regulation of the function of the islets of Langerhans, which stimulates 
insulin secretion and inhibits glucagon. Unlike sulfonylurea, GLP-1 
controls blood glucose levels with dependent glucose properties, thus 
preventing the occurrence of side effects such as hypoglycemia. GLP-1 
also decreases gastrointestinal motility, inhibits gastric emptying, 
decreases food intake and causes weight loss [24]. The central 
mechanism of GLP-1 reduced body weight was inhibit the action of 
neurons that produce the orexigenic neuropeptide Y (NPY) and 
Agouti-related protein (AgRP) and increase the activity of 
proopiomelanocortin neurons (POMC) which produce α-Melanocyte-
stimulating hormone (α-MSH) in the hypothalamus, causing decreased 
appetite and food intake and increased energy expenditure [25]. 
The insulinotropic mechanism of GLP-1 is related to its ability to 
increase Cyclic Adenosine Monophosphate (cAMP) levels and inducing 
glucose metabolism in pancreatic β-cells. The bond between GLP-1 
and its receptor (GPCR) activates the enzyme adenylate cyclase. 
Increased levels of cAMP will cause (1) an increase in glucose 
metabolism to produce ATP, (2) closure of potassium canals and cell 
membrane depolarization, and (3) opening of calcium channels in the 
cell membranes and intracellular calcium depots to increase the 
intracellular calcium levels. Furthermore, increased levels of 
intracellular calcium will cause insulin exocytosis; in addition to 
increasing insulin secretion, GLP-1 also activates glucokinase and 
Glucose Transporter 2 (GLUT2) genes [19, 26]. 
GLP-1 increases the differentiation of progenitor cells in the 
pancreatic ducts into new pancreatic β-cells and inhibits β-cell 
apoptosis through the inhibition of pro-apoptotic cytokines and 
caspase enzyme activity [19]. GLP-1 also has a proliferative effect on 
pancreatic β-cell, which on pancreatic β cells occur via the Epidermal 
Growth Factor Receptor (EFGR) activation mechanism. GLP-1 will 
cause EGFR post-translation. The next signaling activates the 
Phosphoinositide 3-Kinases (PI3K) and causes the translocation of 
FoxO1 from the nucleus to the cytoplasm. The phosphorylation of 
FoxO1 causes the proliferation of pancreatic β-cells [27, 28]. 
FoxO1 is a transcription factor protein which belongs to a family of 
forkhead proteins with the characteristic of having a forkhead 
domain. These transcription factors play a role in regulating the cell 
cycle, cell differentiation, apoptosis and cell resistance to oxidative 
stress [29]. In mammals, there are isoforms from FoxO1, such as 
FoxO3, FoxO4, and FoxO6. FoxO1 is found in the adult pancreatic β-
cells but is not found in other pancreatic cells such as acinus cells, α 
cells, δ cells, and PP cells [30]. 
The role of FoxO1 in pancreatic β-cell proliferation and apoptosis is 
related to the function of the Pancreatic and Duodenal Homeobox 1 
(PDX1 gene). The PDX1 gene is the primary gene that plays a role in 
pancreatic cell embryogenesis. In the embryogenesis phase, the 
PDX1 expression is abundant in pancreatic β-cells, and this 
expression decreases after reaching adulthood. The physiological 
expression of PDX1 is found in the nucleus while FoxO1 is found in 
the cytoplasm [31]. The phosphorylation of FoxO1 is regulated by 
insulin via the phosphoinositide 3 kinase-Akt pathway. 
Phosphorylation of FoxO1 in the cytoplasm activates the work of the 
cyclin D1 and Cyclin Dependent Kinase-4 (CDK4) proteins activating 
the cell cycle from the G0 to G1 phase in preparation for DNA 
synthesis [32]. However, several factors are reported to cause the 
migration of FoxO1 to the nucleus. High blood glucose levels, 
hyperlipidemia, and the aging process are examples of factors that 
cause the migration of FoxO1 to the nucleus [33]. Inside the nucleus, 
FoxO1 will compete with FoxA1 to occupy the PDX1 promoter DNA. 
FoxA1 includes a transcription protein from the Forkhead protein 
family, which is a positive regulator of PDX1. The bond between 
FoxO1 and PDX1 promoters causes apoptosis [31]. 
FoxO1 plays a role in the process of pancreatic endocrine cell 
differentiation. Talchai et al. proved that experimental animals that do 
not express FoxO1 in the cytoplasm of pancreatic β-cells will 
experience hyperglycemia and pancreatic β cell mass reduction after 
stress induction. Based on the in vitro study, it was shown that the cell 
death process did not cause pancreatic β-cell reduction; this occurred 
as the result of the differentiation of β-cells into embryonic progenitor 
cells expressing Neurogenin 3, Oct 4, Nanog, and L-Myc. In addition, it 
was proven that the loss of FoxO1 in the cytoplasm caused an increase 
in the number of α cells, and Pancreatic Peptide (PP) cells, and a 
decrease in pancreatic β-cells characterized by a decrease in the 
activity of the genes activity that control insulin synthesis, GLUT 
transporters, and glucokinase enzyme production [34]. 
Computational approaches have been developed to predict the 
ability of an active compound contained in a plant to produce 
biological effects. One such method is based on molecular docking 
analysis [35]. The principle of molecular docking is to predict the 
ability of a ligand to bind with a target protein to form a stable 
complex. The ability of a ligand to bind to the active site of a receptor 
is then analyzed to assess the strength of activation or inhibition 
[36]. Thus, this study identified the active compounds of soursop leaf 
water extract through physicochemical analyses and GC-MS and 
predicted its mechanism of action as an anti-obesity compound 
based on the in silico analysis. 
MATERIALS AND METHODS 
Experimental design 
This study utilized laboratory-based research to identify the active 
compounds of soursop leaf and computational calculations to predict 
its ability to activate GLP-1R, inhibiting DPP4 and FOXO1 proteins. 
Date and place 
The study was carried out in December 2017 and January 2018. It 
was conducted in the Biochemistry laboratory of Universitas Islam, 
Malang, the Bioinformatics Laboratory of Universitas Brawijaya, 
Malang, and the Mineral and Advanced Materials Laboratory of 
Universitas Negeri Malang. 
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Soursop leaf extraction 
Soursop leaves were obtained from Balai Materia Medika, Batu City, 
East Java. Selected soursop leaves (middle leaf, undamaged, glossy 
surface) were washed and dried in the wind out of direct sunlight 
until they reached 10% moisture content. The dried leaves were 
then milled to form a powder. This powder was placed in a 
decoction pan, and water was added in a 1:10 powder-to-water 
ratio. The bottom of the pan was filled with water and boiled to 100 
◦C. The pan containing the soursop leaf pow der and w ater w as 
placed on the decoction of water for 15 min and stirred 
continuously. After cooling down, the resulting extract was filtered 
using Whatman No. 1 paper [37]. The filtrate was then reduced 
using an evaporator at a temperature of 60 °C until the volume 
reached about 1/3 of the original amount [38]. 
Identification of soursop active compound based on a 
physicochemical method 
The soursop’s active compounds were identified in the laboratory 
using the physicochemical method. Samples (5 g each) were ground 
with a mortar. Then, each sample was inserted into a separating 
funnel which had been filled with a mixture of chloroform and water 
(60 ml: 60 ml) then gently stirred for 20 min. They were incubated 
until 2 layers of chloroform-water were formed followed by the 
separation of the water phase and the chloroform phase. The water 
phase was used to test the secondary metabolites, i.e., flavonoids, 
phenolics, and saponins, while the chloroform phase was used to 
test the alkaloids, terpenoids, and steroids. 
Identification of active ingredients of soursop based on the GC-
MS analysis method 
The water extract (10 ml) was mixed with a hexane solution (1:1 
v/v), and then mixed and separated using a separating funnel. 
Hexane extract was used for GC-MS analysis using Shimadzu GC-MS 
with optimization tools as seen in table 1. 
 
Table 1: GC-MS optimization 
Collum oven temperature 80 °C 
Injection temperature 250 ° C 
Injection mode Split 
Flow control mode Pressure 
Total flow 588.8 ml/min 
Collum flow 1.46 ml/min 
Linier velocity 45.5 cm/sec 
Purge flow 3.0 ml/min 
Split ratio 400 
Oven temperature program 
Ratte Temperature Hold time (min) 
- 80.0 1.00 
10.00 250.0 1.00 
Equilibrium time 3.0 min 
 
The results of the GC-MS analysis were converted based on the 
Wiley8. Lib database. The molecular weights of the active 
compounds were compared with the same molecular weights of 
compounds in the database [39]. The highest Similarity Index (SI) 
molecular wieght between active compound and some compound in 
data base indicated the high validity of identification. 
Analysis based on in silico studies 
The active compounds were downloaded from the PubChem server 
(CID was noted). The potential for activation of GLP-1R, DPP4, and 
FOXO1 protein was analyzed using the Way2drug web server. 
Prediction of potential compounds was indicated by probability 
activity (PA) score. GLP-1R, DPP4 and FOXO1 protein were obtained 
from the protein database server. Drug control was taken from the 
PubChem. The active compound interaction of soursop leaf water 
extract with GLP-1R was predicted by using the STITCH program 
[40]. The PyRx program (autodock vina) was used for the docking 
process [41]. Docking was carried out precisely with 1-cyclohexene-
1-carbonitrile, 6-acettyloxy; 1,2–benzenedicarboxylic acid, dietyl 
ester; 2(E)-tert-butyl-4-methyleneadamantan-2(A)-ol; and 5–
isopropenyl-3, 8-dimethyl-1,2,3,3A, 4,5,6,7–octahydroazulene as a 
ligand and GLP-1R, DPP4 and FoxO1 as the target proteins to be 
compared to controls. The smallest or most negative binding energy 
results showed the best complex conformation. The docking results 
were visualized using Ligandscout and PyMol [42]. 
RESULTS 
Physicochemical Identification of Soursop Leaf 
The physiochemical analyses of the soursop leaf determined that it 
contains many active compounds, including flavonoids, phenols, 
alkaloids, and terpenoids, but did not contain saponins or steroids 
(table 2). 
 
Table 2: List of active compounds found in soursop leaf water extract 
No Compound Test method Color changes Result 
1 Flavonoid HCL 0,2N Brownish yellow Positive 
2 Fenol FeCl3 Purplish blue Positive 
3 Saponin vigorously mixed for 10 s Permanent foam Negative 
4 Alkaloid Meyer reagent White sediment Positive 
5 Terpenoid anhydra acetate+H2SO4 2N Purplish red Positive 
6 Steroid anhydra acetate+H2SO4 2N green Negative 
Note: It was found that soursop leaf water extract contained many active compounds–flavonoids, phenols, alkaloids, and terpenoids–but did not 
contain saponins and steroids. 
 
Identification of soursop leaf water extract active compounds 
based on the GC-MS method 
The active compounds of soursop leaf water extract were 
successfully identified via GC-MS analysis.  
Based on fig. 2 and 3 and table 3 as well as the results on the active 
compounds based on the MS confirmation to the Wiley8. Lib database. 
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Fig. 2: Active compound of soursop results identified via GC-MS analysis, note: soursop leaf water extract was determined to contain 5 






Fig. 3: The mass spectra of the active compounds of soursop obtained via GC-MS analysis, active compound in the first peak (RT 9.546) are 
not identified in data base wileylab8 
 
Table 3: The active compounds obtained based on the GC-MS analysis 
Peak SI R. T Area % MW Name CAS/CID Class Structure 
 2 97 9.608 2.84 165 1-cyclohexene-1-carbonitrile,6- CAS 130251- phenolic  
     acettyloxy 99-9   
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Note: Soursop leaf was containing water extract contain flavonoids, phenols, terpenoids, and alkaloids. SI: similary index, R. T: real time; MW: 
molecular weight 
 
Potential analysis of soursop leaf water extract’s active 
compounds 
Analysis using the Way2drug web server shows that the 5–
isopropenyl-3, 8-dimethyl-1,2,3,3A, 4,5,6,7–octahydroazulene and 
phthalic acid are predicted by bioinformatics to have the ability to be 
antioxidant and insulin promoter (Pa>0,4).  
The interaction prediction of GLP-1R with active compounds of 
soursop leaf water extract 
The interaction of GLP-1R with soursop’s active compounds was 
predicted using the STITCH program. The results of the analysis 
showed that Phthalic acid did not bind to the GLP-1 receptor but 
interacted with hydrogen peroxide (fig. 4). 
 
 
Fig. 4: The active compounds of soursop with the GLP-1 receptor. Active compounds of soursop leaf water extract did not have a 
interactions with GLP-1R 
 
The binding potential of soursop leaf water extracts active 
compounds with the DPP4 and FoxO1 target proteins 
Molecular docking was used to determine the binding potential of 
the active compounds found in the soursop leaf water extract with 
the DPP4 and FoxO1 target proteins. It was also used to determine 
the most active compounds based on the affinity value of each 
compound to a protein. The affinities of the active compounds 
contained in soursop leaf water extract for DPP4 protein were tested 
using Linagliptin, a drug that can inhibit the DPP4 enzyme [43], as a 
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control; it was determined that phthalic acid and 5–isopropenyl-3, 8-
dimethyl-1,2,3,3A, 4,5,6,7–octahydroazulene have lower affinities 
for DPP4 than controls. The affinities of the active compounds 
contained in soursop leaf water extract to FoxO1 protein were 
determined using AS1842856 (PubChem ID: 72193864), a 
compound that can inhibit FoxO-1 [44], as a control. The active 
compound identified as phthalic acid has a lower affinity towards 
the FoxO1 protein than the control (table 4). 
 
Table 4: Molecular docking active ingredient of soursop (A. muricata L.) leaf water extract against DPP4 and FoxO1 target protein 
Active compound Δ G (kkal/mol) against DPP4 
protein 
Δ G (kkal/mol) against FoxO1 
protein 
1-cyclohexene-1-carbonitrile, 6-acettyloxy -6 -3.6 
1,2–benzenedicarboxylic acid, dietyl ester -6 -4.5 
2(E)-tert-butyl-4-methyleneadamantan-2(A)-ol -6.2 -2.4 
5–isopropenyl-3, 8-dimethyl-1,2,3,3A, 4,5,6,7–octahydroazulene -6.9 -3.61 
Kontrol -10 -6.1 
Note: Docking process using the PyRx program (autodock vina). The control of DPP4 inhibitors using Linagliptin. Control of FoxO1 inhibitors using 
AS1842856 (PubChem ID: 72193864). 
 
DISCUSSION 
Identification of the active compounds in soursop leaf water extract 
GC-MS results showed that there are five active compounds in 
soursop leaf water extract. Phthalic acid (57,30%) and 5-
isopropenyl-3,8-dimethyl-1,2,3,3A, 4,5,6,7-octa hydro azulene 
(22,17%) are the most active ingredient contained in soursop leaf 
water extract. There is one active compound unidentified because it 
cannot be found in data base wileylab8. Researchers suspect such 
active compund have never been found previous or not researched 
so this is not recorded in base data used as confirmation. 
Researchers recommend using other tools as confirmation of such 
active materials. 
Potential analysis of soursop leaf water extract’s active compounds 
The potential test results showed that 5–isopropenyl-3, 8-dimethyl-
1,2,3,3A, 4,5,6,7–octahydroazulene and phthalic acid had potential 
as antioxidant and insulin promoters with P (a)>0.4. This indicated 
that computational predictions still required laboratory verification 
both in vitro and in vivo to support these allegations. Previous 
research stated that the water extract of soursop leaves given for 3 
w at 100 mg/kgBW was able to increase endogenous antioxidant 
and increase the serum insulin levels of STZ-induced hyperglycemia 
in mice [45]. However, the active compound(s) that works as an 
insulin promoter has not been identified. 
The interaction prediction of GLP-1R protein with the soursop 
leaf water extract active compounds 
The active compound of soursop leaf water extract has not been 
shown to directly interact with GLP-1R proteins. This is assumed to be 
due to the lack of similarity in the chemical structure of the active 
compounds and GLP-1R, so they are unable to bind to the active site of 
the GLP-1R. Phthalic acid has been shown to interact with hydrogen 
peroxide. This is assumed phthalic acid have antioxidant potency. 
The binding Potential of Soursop Leaf Water Extract’s Active 
Compounds with the DPP4 target protein  
Linagliptin was used as the control in this study. Linagliptin is a drug 
that has the effect of inhibiting DPP4 competitively and reversibly. 
Linagliptin’s inhibition potency to DPP4 was better than related 
drugs, including sitagliptin, vildagliptin, and saxagliptin [43]. From 
the results of molecular docking, it was found that the free bonding 
energy of linagliptin to the DPP4 protein was-10 kcal/mol. This 
indicated that linagliptin has a high affinity with DPP4 and can form 
strong and stable bonds that further inhibit the DPP4. 
Molecular docking results from the active compounds of soursop leaf 
water extract showed that 5-isopropenyl-3,8-dimethyl-1,2,3,3A, 
4,5,6,7-octa hydro azulene (∆G of-6.9 kcal/mol) and phthalic acid 
had the best affinity to the DPP4 protein (∆G of-6.9 kcal/mol) 
compared to other compounds. However, free bonding energy (∆G) 
5-isopropenyl-3,8-dimethyl-1,2,3,3A, 4,5,6,7-octa hydro azulene and 
phthalic acid were greater than control. It can be predicted that 5-
isopropenyl-3,8-dimethyl-1,2,3,3A, 4,5,6,7-octa hydro azulene, and 
phthalic acid have a weak potential to inhibit the DPP4. Although it 
was weak, the synergy found was expected as an insulin promoter 
through the prevention of GLP-1 degradation by DPP4. 
Potential of soursop leaf water extract’s active compounds 
towards the FoxO1 target protein 
AS1842856 was used as a control to determine the affinity of the 
active compounds contained in the water extract of soursop leaf 
with the FoxO1 target protein. AS1842856 is an active small 
molecule identified as 5-amino-7-(cyclohexyl-amino)-1-ethyl-6-
fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (PubChem ID: 
72193864). Based on the in silico analysis, AS1842856 is a 
compound that can inhibit FOXO-1 [44]. Other studies have 
suggested that the in vitro administration of AS1842856 to liver cell 
lines has caused a decrease in glucose production. Based on a 
previous in vivo study, it was also shown that the application of 
AS1842856 was able to reduce blood glucose levels in DM mice [46]. 
The results of previous studies proved that other active compounds 
of soursop leaf, e. g., annonain, routine, muricatocin A, isolaureline, 
xylophone, and kaempferol 3-O-rutinoside, showed affinities with 
the FoxO1 protein with the same or better potential as AS1842856 
based on the in silico analysis [44]. 
The molecular docking results showed that phthalic acid’s active 
compound weakly inhibited FoxO1. The results of ∆G with FoxO1 
indicated it was greater than-7 kcal/mol. In general, the FoxO1 
protein is abundant in the cytoplasm [31]. FoxO1 activation in the 
cytoplasm is regulated by insulin. The phosphorylation of FoxO1 
activates the action of the cyclin D1 and cdk4 proteins, which 
regulate the cell cycle of pancreatic β-cell proliferation [32]. 
However, high glucose levels, hyperlipidemia, and the aging process 
will cause the translocation of FoxO1 to the nucleus [33]. The 
activation of FoxO1 in the nucleus will cause PDX-1 gene inhibition. 
This gene plays a role in regulating pancreatic β-cell proliferation. 
The bond between FoxO1 and PDX1 promoters causes apoptosis 
[31]. FoxO1 plays a role in the process of endocrine cell 
differentiation. FoxO1 activity in the cytoplasm causes the 
differentiation of β-cells into embryonic progenitor cells [34, 47]. 
CONCLUSION 
The active compounds found in soursop leaf water extract were 
phthalic acid (BM 222) (57.30%), and 5-isopropenyl-3,8-dimethyl-
1,2, 3,3A, 4,5,6,7-octahydroazulene (BM 204) (22.17%). These two 
active compounds have a weak affinity with DPP4. Only phthalic acid 
has a weak affinity to FoxO-1. Phthalic acid as predicted was able to 
inhibit DPP4 and FoxO1 activity in the nucleus. However, in vivo 
studies based on research using animal models are needed to verify 
the predictions that have been generated from the computational 
process. 
ACKNOWLEDGMENT 
This article was presented at The 3rd International Conference and 
Exhibition on Indonesian Medical Education and Research Institute 
(ICE on IMERI 2018), Faculty of Medicine, Universitas Indonesia, 
Damayanti et al. 
Int J App Pharm, Vol 11, Special Issue 6, 2019, 72-79 
78 
Jakarta, Indonesia. This research was funded by the Dean of the 
Medical Faculty UNISMA. This research was conducted in 
collaboration with the Bioinformatics from University of Brawijaya, 
research assistant from Medical Faculty UNISMA, and University of 
Malang. We thank the 3rd
AUTHORS CONTRIBUTIONS 
 ICE on IMERI Committee who had 
supported the peer review and manuscript preparation before 
submitting to the journal.  
All the author have contributed equally 
CONFLICT OF INTERESTS 
The authors declared no conflict of interest 
REFERENCES 
1. Budijanto D. Profil Kesehatan Indonesia. Jakarta: Kementerian 
Kesehatan Republik Indonesia; 2017. 
2. Ekor M. The growing use of herbal medicines: issues relating to 
adverse reactions and challenges in monitoring safety. Front 
Pharmacol 2014;4:1-10. 
3. Elfahmi, Woerdenbag HJ, Kayser O. Jamu: Indonesian 
traditional herbal medicine towards rational 
phytopharmacological use. J Herb Med 2014;69:1-23. 
4. Morton, Julia F. The Soursop, Or Guanabana (Annona Muricata). 
Florida Atlantic University; 1966. p. 355-66. 
5. Nwokocha CR, Owu DU, Gordon A, Thaxter K, McCalla G, Ozulua 
RI, et al. Possible mechanisms of action of the hypotensive 
effect of Annona muricata (soursop) in normotensive sprague-
dawley rats. Pharm Biol 2012;50:1436-41.  
6. Florence NT, Benoit MZ, Jonas K, Alexandra T, Desire DD, Pierre 
K, et al. Antidiabetic and antioxidant effects of annona muricata 
(Annonaceae), aqueous extract on streptozotocin-induced 
diabetic rats. J Ethnopharmacol 2014;151:784-90. 
7. Ishola IO, Awodele O, Olusayero AM, Ochieng CO. Mechanisms 
of analgesic and anti-inflammatory properties of annona 
muricata linn. (Annonaceae) fruit extract in rodents. J Med 
Food 2014;17:1375-82. 
8. Cercato LM, White PA, Nampo FK, Santos MR, Camargo EA. A 
systematic review of medicinal plants used for weight loss in 
Brazil: is there potential for obesity treatment? J 
Ethnopharmacol 2015;176:286-96. 
9. George V Cijo. Antioxidant, DNA protective efficacy and HPLC 
analysis. J Food Sci Technol 2015;52:2328–35. 
10. Agbai EO, Njoku CJ, Nwanegwo CO, Nwafor A. Effect of aqueous 
extract of Annona muricata seed on atherogenicity in 
streptozotocin-induced diabetic rats. Afr J Pharm Pharmacol 
2015;9:745-55. 
11. Patel S, Patel JK. A review on a miracle fruits of Annona 
muricata. J Pharmacogn Phtochem 2016;5:137-48. 
12. Pai BHM, Rajesh G, Shenoy R, Rao A. Anti-microbial efficacy of 
soursop leaf extract (Annona muricata) on oral pathogens: an 
in vitro study. J Clin Diagn Res 2016;10:ZC01-ZC04. 
13. Bikomo EO, Ebuehi OAT, Magbagbeola A. Antidepressant 
activity of ethanol leaf extract of annona muricata L, in 
spraque-dawley rats. Am J Biochem 2017;7:1-5. 
14. Yajid AI, Ab Rahman HS, Wong MPK, Zain WZW. Potential 
benefits of annona muricata. Malays J Med Sci 2018;25:5-15. 
15. Moghadamtousi SZ, Fadaeinasab M, Nikzad S, Mohan G, Ali HM, 
Kadir HA. Annona muricata (Annonaceae): a review of its 
traditional uses, isolated acetogenins and biological activities. 
Int J Mol Sci 2015;16:15625-58. 
16. Nik Mat Daud MM, Yaakob H, Mohamad Rosdi MN. Acetogenins 
of annona muricata leaves: characterization and potential 
anticancer study. Integr Cancer Sci Therap 2016;3:543-51.  
17. James WP. WHO recognition of the global obesity epidemic. Int 
J Obes 2008;32(Suppl 7):S120–S126. 
18. Segula D. Complications of obesity in adults: a short review of 
literature. Malawi Med J 2014;26:20-4. 
19. Garber AJ. Long-acting glucagon-like peptide 1 receptor 
agonists. Diabetes Care 2011;34(Suppl 2):S279-S282. 
20. Madsbad S. The role of glucagon-like peptide-1 impairment in 
obesity and potential therapeutic implications. Diabetes Obes 
Metab 2014;16:9-21. 
21. Harbener JF, Kiefer TJ. Glucagon and glucagon like peptides. In: 
Joslin’s Diabetes Mellitus. 14th edition. Editor. CR Kahn, GL 
King, AC Moses, GC Weir, AM Jacobson, RJ Smith. Philadelphia: 
Lippincott Willams and Wilkins; 2005. p. 179-90. 
22. Sandoval DA, Dalessio DA. Physiology of proglucagon peptides: 
role of glucagon and GLP-1 in health and disease. Physiol Rev 
2015;95:513-48. 
23. Donnelly D. The structure and function of glucagon-like 
peptide-1 and its ligands. Br J Pharmacol 2012;166:27–41. 
24. Druker DJ, Sherman SI, Gorelick FS, Bergenstal RM, Sherwin RS, 
Buse JB. Incretin-based therapies for the treatment of type 2 
diabetes: evaluation of the risks and benefits. Diabetes Care 
2010;33:428-33. 
25. Van Bloemendaal L, Ten Kulve JS, Ia Fleur SE, Ijzerman RG, 
Diamant M. Effects of glucagon-like peptide 1 on appetite and 
body weight: focus on the CNS. J Endocrinol 2014;221:T1-16. 
26. Reimann F, Gribble FM. Mechanisms underlying glucose-
dependent insulinotropic polypeptide and glucagon-like peptide-1 
secretion. J Diabetes Investigation 2016;7(Suppl 1):13-9. 
27. Buteau J, Spatz ML, Accili D. Transcription factor FoxO1 
mediates glucagon-like peptide-1 effects on pancreatic beta-cell 
mass. Diabetes 2006;55:1190-6. 
28. Fusco J, Xiao X, Prasadan K, Sheng Q, Chen C, Ming YC. GLP-
1/Exendin-4 induces β-cell proliferation via the epidermal 
growth factor receptor. Sci Rep 2017;7:1-6. 
29. Greer EL, Brunet A. FOXO transcription factors at the interface 
between longevity and tumor suppression. Oncogene 
2005;24:7410-25. 
30. Kitamura T, Ido Kitamura Y. Role of FoxO proteins in pancreatic 
beta cells. Endocr J 2007;54:507-15. 
31. Kitamura YI, Kitamura T, Kruse JP, Raum JC, Stein R, Gu W, et al. 
FoxO1 protects against pancreatic beta cell failure through 
NeuroD and MafA induction. Cell Metab 2005;2:153-63. 
32. Okamoto H, Hribal ML, Lin HV, Bennett WR, Ward A, Accili D. 
Role of the forkhead protein FoxO1 in beta cell compensation 
to insulin resistance. J Clin Invest 2006;116:775-82. 
33. Gross DN, Van den Heuvel AP, Birnbaum MJ. The role of FoxO in 
the regulation of metabolism. Oncogene 2008;27:2320-36. 
34. Talchai C, Xuan S, Lin HV, Sussel L, Accili D. Pancreatic β-cell 
dedifferentiation as mechanism of diabetic β-cell failure. Cell 
2012;150:1223-34. 
35. Wadood A, Ahmed N, Shah L, Ahmad A, Hassan H, Shams S. In 
silico drug design: An approach which revolutionarised the 
drug discovery process. OA Drug Design Delivery 2013;1:3. 
36. De Ruyck J, Brysbaert G, Blossey R, Lensink MF. Molecular 
docking as a popular tool in drug design, an in silico travel. Adv 
Appl Bioinform Chem 2016;9:1-11. 
37. Félix Silva J, Souza T, Menezes YA, Cabral B, Camara B, Camara 
RB, et al. Aqueous leaf extract of Jatropha gossypiifolia L. 
(Euphorbiaceae) inhibits enzymatic and biological actions of 
bothrops jararaca snake venom. PLoS One 2014;9:e104952. 
38. Oyedeji O, Taiwo FO, Ajayi OS, Ayinde F, Oziegbe M, Oseghare 
CO. Biocidal and phytochemical analysis of leaf extracts of 
annona muricata (Linn.). Int J Sci: Basic Appl Res 2015;24:76-
87. 
39. Ezhilan BP, Neelamegam R. GC-MS analysis of 
phytocomponents in the ethanol extract of polygonum 
chinense L. Pharmacognosy Res 2012;4:11-4. 
40. Szklarczyk D, Santos A, Von Mering C, Jensen LJ, Bork P, Kuhn 
M. STITCH 5: augmenting protein–chemical interaction 
networks with tissue and affinity data. Nucleic Acids Res 
2016;44:D380–D384. 
41. Dallakyan S, Olson AJ. Small-molecule library screening by 
docking with PyRx. Methods Mol Biol 2015;1263:243-50. 
42. Seeliger D, de Groot BL. Ligand docking and binding site 
analysis with PyMOL and Autodock/Vina. J Computer Aided 
Mol Des 2010;24:417–22. 
43. Gallwitz B. Emerging DPP-4 inhibitors: focus on linagliptin for 
type 2 diabetes diabetes. Diabetes Metab Syndr Obes 2013;6:1-
9. 
44. Damayanti DS, Utomo DH, Kusuma C. Revealing the potency of 
Annona muricata leaves extract as FOXO1 inhibitor for diabetes 
mellitus treatment through computational study. In Silico 
Pharmacol 2016;5:3.  
Damayanti et al. 
Int J App Pharm, Vol 11, Special Issue 6, 2019, 72-79 
79 
45. Adewole SO, Ojewole JA. Protective effects of annona muricata 
Linn. (Annonaceae) leaf aqueous extract on serum lipid profiles 
and oxidative stress in hepatocytes of streptozotocin-treated 
diabetic rats. Afr J Traditional 2008;6:30-41. 
46. Nagashima T, Shigematsu N. Maruki R, Urano Y, Tanaka H, 
Shimaya A, et al. Discovery of novel forkhead box O1 inhibitors 
for treating type 2 diabetes: improvement of fasting glycemia in 
diabetic db/db mice. Mol Pharmacol 2010;78:961–70. 
47. Zhang T, Kim DH, Xiao X, Lee S, Gong Z, Muzumdar R. FoxO1 
plays an important role in regulating-cell compensation for 
insulin resistance in male mice. Endocrinology 2016; 
157:1055–70.
 
